Macrolides

Results: 352



#Item
111June 23, 2008 Submit an sNDA for the immunosuppressant Prograf® for Ulcerative Colitis in Japan Japan, June 23, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) to

June 23, 2008 Submit an sNDA for the immunosuppressant Prograf® for Ulcerative Colitis in Japan Japan, June 23, [removed]Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) to

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2008-09-17 23:51:41
112September 19, 2007 Astellas Submitted a Response to the FDA Action Letter for FK506 Modified Release Formulation for Kidney Transplantation Japan, September 19, [removed]Astellas Pharma Inc. (headquarters: Tokyo, presiden

September 19, 2007 Astellas Submitted a Response to the FDA Action Letter for FK506 Modified Release Formulation for Kidney Transplantation Japan, September 19, [removed]Astellas Pharma Inc. (headquarters: Tokyo, presiden

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2008-09-18 20:50:47
113Brigham and Woman’s Hospital/ Harvard Medical School Boston, USA Department of Translational Medicine (Director: Thomas P. Stossel, MD) and

Brigham and Woman’s Hospital/ Harvard Medical School Boston, USA Department of Translational Medicine (Director: Thomas P. Stossel, MD) and

Add to Reading List

Source URL: www.marshallplan.at

Language: English - Date: 2014-09-30 20:59:05
114Torisel® (temsirolimus) for Kidney Cancer Indication: Torisel is a medication used to treat advanced kidney cancer in adults Dosage: 25 mg Route of administration: Intravenous infusion Schedule: Once a week What is the

Torisel® (temsirolimus) for Kidney Cancer Indication: Torisel is a medication used to treat advanced kidney cancer in adults Dosage: 25 mg Route of administration: Intravenous infusion Schedule: Once a week What is the

Add to Reading List

Source URL: dev66.geckodesigns.com

Language: English - Date: 2014-10-30 16:14:47
115November 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, I

November 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, I

Add to Reading List

Source URL: files.shareholder.com

Language: English
116Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Pediatric Postmarketing Pharmacovigilance and Dru

Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Pediatric Postmarketing Pharmacovigilance and Dru

Add to Reading List

Source URL: www.fda.gov

Language: English
117NIH Public Access Author Manuscript J Natl Cancer Inst. Author manuscript; available in PMC 2009 July 1. NIH-PA Author Manuscript

NIH Public Access Author Manuscript J Natl Cancer Inst. Author manuscript; available in PMC 2009 July 1. NIH-PA Author Manuscript

Add to Reading List

Source URL: www.bhdsyndrome.org

Language: English - Date: 2011-03-17 20:08:21
118HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ELIDEL® safely and effectively. See full prescribing information for ELIDEL®. ELIDEL® (pimecrolimus) Cream, 1% fo

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ELIDEL® safely and effectively. See full prescribing information for ELIDEL®. ELIDEL® (pimecrolimus) Cream, 1% fo

Add to Reading List

Source URL: elidel-us.com

Language: English - Date: 2014-06-19 10:56:32
119Microsoft Word - Tacrolimus NDA Acceptance Release FINAL.docx

Microsoft Word - Tacrolimus NDA Acceptance Release FINAL.docx

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2012-12-04 18:27:38
120Award ID: RP130276 Project Title: The mTOR-dependent nuclear transport in cancer Award Mechanism: Individual Investigator

Award ID: RP130276 Project Title: The mTOR-dependent nuclear transport in cancer Award Mechanism: Individual Investigator

Add to Reading List

Source URL: www.cprit.state.tx.us

Language: English - Date: 2014-11-20 01:49:18